Advicenne Completes European Commercial Coverage of Sibnayal(R) Through Its Agreement with Avanzanite Bioscience
regulatory authorities, as well as marketing and commercial activities. Advicenne will continue to hold the marketing authorization (MA) for Sibnayal(R) in the European Union. In Switzerland, Avanzanite will be responsible for filing the marketing authorization. In return, like with its existing agreements, Advicenne will receive the proceeds from the sale
of Sibnayal(R) in the form of a transfer price and royalties. With this agreement allowing Sibnayal(R) to be made available to German patients, Advicenne has completed its coverage
of the five major European countries, either on its own or through partnerships. Sibnayal(R) is now being marketed throughout Europe which should significantly improve access to care for patients, and drive sales from 2023 onward.